Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioAtlaBCAB -4.76%17 Days Sales Outstanding is 28.08 as of Jun. 2026. GuruFocus rates BCAB with a GF Score™ of 17/100. The stock has 3 warning signs investors should review. Among 841 Biotechnology companies, BioAtla ranks worse than 60.52% on this metric.
BioAtla's average Accounts Receivable for the
three
months ended in Jun. 2026 was $2.00 Mil. BioAtla's Revenue for the
three
months ended in Jun. 2026 was $6.50 Mil.
Hence, BioAtla's Days Sales Outstanding for the
three
months ended in Jun. 2026 was 28.08.
The historical rank and industry rank for BioAtla's Days Sales Outstanding or its related term are showing as below:
BCAB'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 0 Med: 0 Max: 85.88
Current: 85.88
During the past 8 years, BioAtla's highest Days Sales Outstanding was 85.88. The lowest was 0.00. And the median was 0.00.
BCAB's Days Sales Outstanding is ranked worse than 60.52% of 841
companies
in the Biotechnology industry
Industry Median: 68.98
vs BCAB: 85.88
BioAtla's Days Sales Outstanding
increased
from Jun. 2025 (0.00) to Jun. 2026 (28.08).
BioAtla (OTCPK:BCAB) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
BioAtla Days Sales Outstanding Related Terms
BioAtla Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for BioAtla's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BCAB vs MTNB, GNPX, ISCO: Days Sales Outstanding Comparison
For the Biotechnology subindustry, BioAtla's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioAtla Days Sales Outstanding vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioAtla's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where BioAtla's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioAtla (BCAB) has a Days Sales Outstanding of 28.08 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on BioAtla and its competitors. According to the industry distribution chart, BioAtla ranks #509 out of 841 companies in the Biotechnology industry, placing it in the top 60.5%.
Is BioAtla's Days Sales Outstanding too high?
BioAtla's current Days Sales Outstanding is 28.08. The Biotechnology industry median Days Sales Outstanding is 68.98. BioAtla's value of 28.08 is 59.3% below this industry median. Based on the distribution chart, BioAtla ranks #509 out of 841 companies in the Biotechnology industry, which is below the industry midpoint. Overall, BioAtla has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does BioAtla's Days Sales Outstanding compare to MTNB and GNPX?
According to the Biotechnology industry distribution chart, BioAtla ranks #509 out of 841 companies for Days Sales Outstanding. This places BioAtla in the lower half of its industry. The industry median Days Sales Outstanding is 68.98. BioAtla's value of 28.08 is 59.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 68.98, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioAtla's current Days Sales Outstanding of 28.08 is 59.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on BioAtla and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 68.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioAtla's current Days Sales Outstanding is 28.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioAtla stock overvalued right now?
BioAtla (BCAB) has a current Days Sales Outstanding of 28.08. The current Days Sales Outstanding is 28.08 and 59.3% below the Biotechnology industry median of 68.98. BioAtla's overall GF Score™ is 17/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For BioAtla (BCAB), the current Days Sales Outstanding is 28.08 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs. The company's operations are organized on a single reportable segment, which includes all activities related to the discovery, development, and commercialization of its CAB products.
17GF Score
Get the complete analysis for BCAB
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BCAB has been successfully added to your 
